Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Cerilliant
AstraZeneca
Fish and Richardson
Moodys
Harvard Business School
Medtronic
US Department of Justice

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALCOHOL 5% IN DEXTROSE 5%

« Back to Dashboard

Clinical Trials for Alcohol 5% In Dextrose 5%

Trial ID Title Status Sponsor Phase Summary
NCT00000152 Randomized Trial of Beta-Carotene and Macular Degeneration Unknown status National Eye Institute (NEI) Phase 3 To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
NCT00000159 Sorbinil Retinopathy Trial (SRT) Completed National Eye Institute (NEI) Phase 3 To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00000161 Randomized Trials of Vitamin Supplements and Eye Disease Unknown status National Eye Institute (NEI) Phase 3 To determine whether vitamin E supplementation reduces the risk of cataract and age-related macular degeneration (AMD) in women. To determine whether vitamin C supplementation reduces the risk of cataract and AMD in women. To determine whether beta-carotene supplementation reduces the risk of cataract and AMD in women. To determine whether alternate day, low-dose aspirin reduces the risk of cataract and AMD in women. To identify potential risk factors for cataract and AMD including cigarette smoking, alcohol intake, blood pressure, blood cholesterol, cardiovascular disease, height, body mass index, and diabetes.
NCT00000257 Effects of Alcohol History on Effects of Nitrous Oxide - 9 Completed National Institute on Drug Abuse (NIDA) N/A The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To determine effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers.
NCT00000257 Effects of Alcohol History on Effects of Nitrous Oxide - 9 Completed University of Chicago N/A The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To determine effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers.
NCT00000261 Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to evaluate the effects of alcohol history on the subjective and reinforcing effects of sevoflurane and nitrous oxide in healthy volunteers. All subjects underwent psychomotor testing during 4 sessions of placebo, drug/placebo, and choice of intervention.
NCT00000261 Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13 Completed University of Chicago Phase 2 The purpose of this study is to evaluate the effects of alcohol history on the subjective and reinforcing effects of sevoflurane and nitrous oxide in healthy volunteers. All subjects underwent psychomotor testing during 4 sessions of placebo, drug/placebo, and choice of intervention.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Alcohol 5% In Dextrose 5%

Condition Name

Condition Name for Alcohol 5% In Dextrose 5%
Intervention Trials
Alcoholism 175
Alcohol Dependence 151
Alcohol Use Disorder 63
Alcohol Abuse 44
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Alcohol 5% In Dextrose 5%
Intervention Trials
Alcoholism 342
Disease 138
Alcohol Drinking 121
Depression 49
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Alcohol 5% In Dextrose 5%

Trials by Country

Trials by Country for Alcohol 5% In Dextrose 5%
Location Trials
Canada 85
United Kingdom 41
Germany 35
Brazil 25
India 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Alcohol 5% In Dextrose 5%
Location Trials
California 130
Texas 101
New York 96
Maryland 96
Connecticut 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Alcohol 5% In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Alcohol 5% In Dextrose 5%
Clinical Trial Phase Trials
Phase 4 308
Phase 3 183
Phase 2/Phase 3 50
[disabled in preview] 580
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Alcohol 5% In Dextrose 5%
Clinical Trial Phase Trials
Completed 746
Recruiting 277
Not yet recruiting 116
[disabled in preview] 256
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Alcohol 5% In Dextrose 5%

Sponsor Name

Sponsor Name for Alcohol 5% In Dextrose 5%
Sponsor Trials
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 195
National Institute on Drug Abuse (NIDA) 71
Yale University 67
[disabled in preview] 116
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Alcohol 5% In Dextrose 5%
Sponsor Trials
Other 1574
NIH 399
Industry 339
[disabled in preview] 103
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Healthtrust
US Department of Justice
Baxter
Colorcon
Chubb
Farmers Insurance
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.